Outcome of MC patients treated by immunotherapy
| Patient no. . | Donor (source) . | Disease status . | 1st MC, d Chim (PB or BM/subpop) . | Withdrawal of IS, d . | 1st DLI, d . | No. of DLIs . | Maximal no. of CD3+ cells/kg/DLI . | Restored CC, d . | aGvHD before IT, grade . | aGvHD after IT, grade . | cGvHD, grade . | 2nd MC, d Chim (PB or BM/subpop) . | Last FU . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MMFD (BM) | NR | 29/- | 31 | No | 35 | No | IV | No | 105/- | Relapsed | ||
| 2 | MMFD (PBSC, 1st SCT) MUD (BM, 2nd SCT) | NR (1st SCT) NR (2nd SCT) | 22/31 | Not given (1st SCT) 17 (2nd SCT) | No (1st SCT) No (2nd SCT) | No (1st SCT) 25 (2nd SCT) | I | I (1st SCT) IV (2nd SCT) | No No | No 38 | Relapsed | ||
| 3 | MUD (PBSC) | CR2 | 125 | 125 | 153 | 3 | 5 × 106 | 188 | I | I | No | No | Relapsed |
| 4 | MMFD (PBSC) | NR | 67/60 | 98 | 76 | 2 | 0.8 × 106 | 108 | I | IV | No | 124/MC | Relapsed |
| 5 | MMFD (PBSC) | NR | 40/40 | 18 | 43 | 1 | 0.025 × 106 | 50 | No | No | No | 61/MC | Relapsed |
| 6 | MUD (BM) | NR | 178/104 | no | 181 | 2 | Σ 6 × 106 | 240 | I | III | Yes (extensive) | No | Relapsed |
| 7 | MUD (PBSC) | CR2 | 82/61 | 82 | No | No | No | I | No | Relapsed | |||
| 8 | MUD (BM) | CR2 | 21/21 | 51 | No | 69 | No | I | No | No | Alive, CCR | ||
| 9 | MUD (BM) | CR1 | 69/69 | 64 | 132 | 4 | 5 × 106 | 266 | I | II | Yes (limited) | No | Alive, CCR |
| 10 | MUD (BM) | NR | 926 | no | 1007 | 9 | 1 × 106 | 1262 | No | No | No | No | Alive, CCR |
| 11 | MUD (PBSC) | CR1 | 84/57 | 89 | No | 103 | I | I | No | No | Alive, CCR | ||
| 12 | MSD (PBSC) | CR1 | 30 | 41 | 42 | 12 | 22 × 106 | 785 | No | I | No | No | Alive, CCR |
| 13 | MSD (BM) | CR1 | 29/29 | 54 | 127 | 17 | 50 × 106 | 33/1042 | I | I | No | No | Alive, CCR |
| Patient no. . | Donor (source) . | Disease status . | 1st MC, d Chim (PB or BM/subpop) . | Withdrawal of IS, d . | 1st DLI, d . | No. of DLIs . | Maximal no. of CD3+ cells/kg/DLI . | Restored CC, d . | aGvHD before IT, grade . | aGvHD after IT, grade . | cGvHD, grade . | 2nd MC, d Chim (PB or BM/subpop) . | Last FU . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MMFD (BM) | NR | 29/- | 31 | No | 35 | No | IV | No | 105/- | Relapsed | ||
| 2 | MMFD (PBSC, 1st SCT) MUD (BM, 2nd SCT) | NR (1st SCT) NR (2nd SCT) | 22/31 | Not given (1st SCT) 17 (2nd SCT) | No (1st SCT) No (2nd SCT) | No (1st SCT) 25 (2nd SCT) | I | I (1st SCT) IV (2nd SCT) | No No | No 38 | Relapsed | ||
| 3 | MUD (PBSC) | CR2 | 125 | 125 | 153 | 3 | 5 × 106 | 188 | I | I | No | No | Relapsed |
| 4 | MMFD (PBSC) | NR | 67/60 | 98 | 76 | 2 | 0.8 × 106 | 108 | I | IV | No | 124/MC | Relapsed |
| 5 | MMFD (PBSC) | NR | 40/40 | 18 | 43 | 1 | 0.025 × 106 | 50 | No | No | No | 61/MC | Relapsed |
| 6 | MUD (BM) | NR | 178/104 | no | 181 | 2 | Σ 6 × 106 | 240 | I | III | Yes (extensive) | No | Relapsed |
| 7 | MUD (PBSC) | CR2 | 82/61 | 82 | No | No | No | I | No | Relapsed | |||
| 8 | MUD (BM) | CR2 | 21/21 | 51 | No | 69 | No | I | No | No | Alive, CCR | ||
| 9 | MUD (BM) | CR1 | 69/69 | 64 | 132 | 4 | 5 × 106 | 266 | I | II | Yes (limited) | No | Alive, CCR |
| 10 | MUD (BM) | NR | 926 | no | 1007 | 9 | 1 × 106 | 1262 | No | No | No | No | Alive, CCR |
| 11 | MUD (PBSC) | CR1 | 84/57 | 89 | No | 103 | I | I | No | No | Alive, CCR | ||
| 12 | MSD (PBSC) | CR1 | 30 | 41 | 42 | 12 | 22 × 106 | 785 | No | I | No | No | Alive, CCR |
| 13 | MSD (BM) | CR1 | 29/29 | 54 | 127 | 17 | 50 × 106 | 33/1042 | I | I | No | No | Alive, CCR |
chim PB indicates chimerism analysis of a PB sample; chim BM, chimerism analysis of a BM sample; chim subpop, chimerism analysis of CD33+ and CD34+ cells within a BM sample; IS, immunosuppression (CSA, cyclosporine A; MMF, mycophenolate mofetil); d, days after transplantation; IT, immunotherapy; and FU, follow-up.